image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - GB
$ 10.46
-0.294 %
$ 47.2 B
Market Cap
24.85
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HLN stock under the worst case scenario is HIDDEN Compared to the current market price of 10.5 USD, Haleon plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HLN stock under the base case scenario is HIDDEN Compared to the current market price of 10.5 USD, Haleon plc is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one HLN stock under the best case scenario is HIDDEN Compared to the current market price of 10.5 USD, Haleon plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HLN

image
$10.8$10.8$10.6$10.6$10.4$10.4$10.2$10.2$10.0$10.0$9.8$9.8$9.6$9.6$9.4$9.4$9.2$9.2$9.0$9.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
11.2 B REVENUE
-0.61%
2.21 B OPERATING INCOME
10.52%
1.44 B NET INCOME
29.79%
2.3 B OPERATING CASH FLOW
9.57%
528 M INVESTING CASH FLOW
494.03%
-1.54 B FINANCING CASH FLOW
1.98%
2.76 B REVENUE
-0.76%
350 M OPERATING INCOME
-50.35%
231 M NET INCOME
-52.37%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Haleon plc
image
Current Assets 5.72 B
Cash & Short-Term Investments 2.25 B
Receivables 2.06 B
Other Current Assets 1.41 B
Non-Current Assets 28.6 B
Long-Term Investments 82 M
PP&E 1.92 B
Other Non-Current Assets 26.6 B
6.56 %5.99 %4.12 %5.60 %77.50 %Total Assets$34.3b
Current Liabilities 5.81 B
Accounts Payable 1.97 B
Short-Term Debt 1.58 B
Other Current Liabilities 2.26 B
Non-Current Liabilities 12.3 B
Long-Term Debt 8.71 B
Other Non-Current Liabilities 3.57 B
10.91 %8.72 %12.50 %48.15 %19.73 %Total Liabilities$18.1b
EFFICIENCY
Earnings Waterfall Haleon plc
image
Revenue 11.2 B
Cost Of Revenue 4.28 B
Gross Profit 6.95 B
Operating Expenses 4.74 B
Operating Income 2.21 B
Other Expenses 764 M
Net Income 1.44 B
12b12b10b10b8b8b6b6b4b4b2b2b0011b(4b)7b(5b)2b(764m)1bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.75% GROSS MARGIN
60.75%
19.64% OPERATING MARGIN
19.64%
12.84% NET MARGIN
12.84%
8.92% ROE
8.92%
4.20% ROA
4.20%
5.68% ROIC
5.68%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Haleon plc
image
3b3b2b2b2b2b1b1b500m500m00202020202021202120222022202320232024202420252025
Net Income 1.44 B
Depreciation & Amortization 324 M
Capital Expenditures -250 M
Stock-Based Compensation 102 M
Change in Working Capital 48 M
Others 529 M
Free Cash Flow 2.05 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Haleon plc
image
Wall Street analysts predict an average 1-year price target for HLN of $10.2 , with forecasts ranging from a low of $10.2 to a high of $10.2 .
HLN Lowest Price Target Wall Street Target
10.2 USD -2.49%
HLN Average Price Target Wall Street Target
10.2 USD -2.49%
HLN Highest Price Target Wall Street Target
10.2 USD -2.49%
Price
Max Price Target
Min Price Target
Average Price Target
1111111110101010999988Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0.117 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.25000000.25000000.20000000.20000000.15000000.15000000.10000000.10000000.05000000.05000000.00000000.00000000.05770.106350.116610.04599360.220.0514160.160.00202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Haleon plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
UK's Haleon takes full control of Chinese consumer healthcare venture British consumer healthcare group Haleon said on Tuesday it has gained complete ownership of its Chinese joint venture after acquiring Tianjin Pharmaceutical Da Ren Tang's 12% stake for about 1.62 billion yuan ($221.4 million). reuters.com - 2 weeks ago
Does defensive Haleon have a cure for the current market blues? Citi believes Haleon PLC (LSE:HLN, NYSE:HLN) is well positioned for the current uncertain climate, describing the consumer healthcare group as a solid defensive play for investors concerned about recession risks and the fallout from Donald Trump's new tariff regime. Shares in the maker of household brands such as Sensodyne and Panadol, have been under pressure amid broader worries over US consumer demand and a tough comparison with last year's strong flu season. proactiveinvestors.co.uk - 3 weeks ago
Haleon: A Defensive Play That Makes Sense Amidst The Stock Market Sell-Off As a hybrid healthcare and consumer staple stock, Haleon offers plenty of stability amidst the current market volatility, with its Power Brands driving strong organic growth. Room for expanding margins and further debt reduction on a net debt/adjusted EBITDA basis (now 2.8x from 4.0x) demonstrate financial strength in uncertain economic conditions. Robust dividend coverage (2.5x covered by earnings) with steady growth and the strategic streamlining of its portfolio highlights Haleon as a reliable defensive investment. seekingalpha.com - 1 month ago
Haleon buys £170m of shares as Pfizer offloads final stake Haleon PLC (LSE:HLN, NYSE:HLN) has bought roughly £170 million of its shares back from former parent company Pfizer Inc (NYSE:PFE, ETR:PFE).   The FTSE 100-listed maker of toothpaste and vitamins paid 385p per share for the off-market purchase, which is part of a previous agreement when Haleon was spun out in 2022 that its former parent companies, GSK being the other, would eventually cut their stakes. proactiveinvestors.co.uk - 1 month ago
Pfizer sells entire Haleon stake for $3.24 billion Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said on Wednesday. reuters.com - 1 month ago
Pfizer to dispose of entire Haleon stake Haleon shareholder Pfizer will dispose of its entire 7.3% stake in the British consumer healthcare group, a bookrunner said on Tuesday. reuters.com - 1 month ago
2 Attractively Priced, High Yield Stocks For Income Durability As The Market Hits New Highs Hyperinflation and high interest rates make dividend-paying stocks attractive, providing cash flow and alleviating inflation pressure. Pfizer's 6% yield is appealing despite recent stock declines, with a low forward multiple and management's commitment to maintaining dividends. Cost savings and Haleon share sales should support Pfizer's dividend yield, with free cash flow expected to improve next year. seekingalpha.com - 1 month ago
Haleon: Growing Profits And Dividend I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by free cash flow, but the 1.6% yield is less attractive compared to peers. The balance sheet is manageable with net debt at 22% of market cap, though I question the optimality of share buybacks at current prices. seekingalpha.com - 1 month ago
Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025 London-based consumer healthcare group Haleon Plc HLN stock is trading lower on Thursday. benzinga.com - 2 months ago
Haleon CEO: We're relatively low-exposed to tariffs Haleon CEO Brian McNamara says his company is not as exposed as peers to tariff risks, as the consumer healthcare company reports full-year results youtube.com - 2 months ago
Haleon figures meet expectations; but analysts and investors wanted more Haleon PLC's (LSE:HLN, NYSE:HLN) prelims have reassured investors, with earnings per share (EPS) beating expectations by 6% in the second half of 2024, according to analysts - although the shares succumbed to a bout of profit taking in their wake. The consumer health giant reported 5% organic growth for the year, slightly ahead of market forecasts, Stifel said. proactiveinvestors.co.uk - 2 months ago
Haleon plc (HLN) Q4 2024 Earnings Call Transcript Haleon plc (NYSE:HLN ) Q4 2024 Earnings Conference Call February 27, 2025 4:00 AM ET Company Participants Jo Russell - Head-Investor Relations Brian McNamara - Chief Executive Officer Dawn Allen - Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS David Hayes - Jefferies Rashad Kawan - Morgan Stanley Chris Pitcher - Redburn Tom Sykes - Deutsche Bank Jo Russell Good morning, everyone. Welcome to Haleon's Full Year 2024 Q&A call. seekingalpha.com - 2 months ago
8. Profile Summary

Haleon plc HLN

image
COUNTRY GB
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 47.2 B
Dividend Yield 0.00%
Description Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Contact Building 5, Weybridge, KT13 0NY https://www.haleon.com
IPO Date July 25, 2022
Employees 24561
Officers Mr. Filippo Lanzi President of EMEA & LatAm Mr. Keith Choy President of Asia Pacific Ms. Dawn Amanda Allen Chief Financial Officer & Director Ms. Tamara Rogers Chief Marketing Officer Ms. Lisa Paley President of North America Ms. Claire Dickson Chief Digital & Technology Officer Ms. Line De Decker Chief Human Resources Officer Mr. Brian James McNamara Chief Executive Officer & Executive Director Mr. Adrian Charles Morris General Counsel Mr. Franck Riot Chief R&D Officer